CD34 and leukemia: Notably, three case studies in dogs diagnosed with CD34+ spontaneous leukemia, roughly equivalent to human Phase 1 clinical trials, demonstrated the ability of DMAPT to reduce the number of leukemia stem cells in both peripheral blood and bone marrow, independently confirming the ability of STLs to suppress tumor stemness in a non-murine model [136].